The Corona Remedies Ltd. Address IPO is a closed mainboard Bookbuilding offer (Offer For Sale) that opened on 8 December 2025. The Corona Remedies Ltd. Address IPO closed on 10 December 2025, with an issue price of ₹1,062 per share. The Corona Remedies Ltd. Address IPO has a face value of ₹10 and a lot size of 14 shares. The Corona Remedies Ltd. Address IPO is listed on 15 December 2025. The Corona Remedies Ltd. Address IPO allotment was scheduled for 11 December 2025.
On the financial front, the Corona Remedies Ltd. Address IPO reported revenue of ₹349 crore for 30 Jun 2025, compared with ₹1,202 crore for 31 Mar 2025. The Corona Remedies Ltd. Address IPO PAT was ₹46 crore against ₹149 crore. The Corona Remedies Ltd. Address IPO EBITDA stood at ₹72 crore with a 20.55% margin. The Corona Remedies Ltd. Address IPO net worth as of 30 Jun 2025 was ₹607 crore.
Always verify The Corona Remedies Ltd. Address IPO details and GMP data with the official offer document before investing in the Corona Remedies Ltd. Address IPO.
Financial Summary
Amount in ₹ Crore
Metric
30 Jun 2025
31 Mar 2025
31 Mar 2024
Total Assets
1,012
930
831
Revenue
349
1,202
1,021
PAT
46
149
91
EBITDA
72
246
161
Net Worth
607
606
480
Reserves
546
545
419
Total Borrowing
107
63
134
Corona Remedies Ltd. Address IPO Financials FAQs
Revenue of Corona Remedies Ltd. Address (Amount in ₹ Crore) — 30 Jun 2025: 349; 31 Mar 2025: 1,202; 31 Mar 2024: 1,021. Profit after tax (PAT) — 30 Jun 2025: 46; 31 Mar 2025: 149; 31 Mar 2024: 91.
EBITDA of Corona Remedies Ltd. Address (Amount in ₹ Crore) — 30 Jun 2025: 72; 31 Mar 2025: 246; 31 Mar 2024: 161. The EBITDA margin is 20.55%.
Total assets — 30 Jun 2025: 1,012; 31 Mar 2025: 930; 31 Mar 2024: 831. Net worth — 30 Jun 2025: 607; 31 Mar 2025: 606; 31 Mar 2024: 480. Reserves & surplus — 30 Jun 2025: 546; 31 Mar 2025: 545; 31 Mar 2024: 419. (Amount in ₹ Crore)
Total borrowing of Corona Remedies Ltd. Address (Amount in ₹ Crore) — 30 Jun 2025: 107; 31 Mar 2025: 63; 31 Mar 2024: 134. Debt-to-equity ratio: 0.10.
The financials shown for Corona Remedies Ltd. Address IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.
